Valneva SE
0OB3.L
London Stock Exchange2.28
EUR
-0.02
- -
Valneva SE
0OB3.L
(London Stock Exchange)
Recent
price
2.28
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Valneva SE (Ticker: 0OB3.L) is a fully integrated, commercial-stage biotech company focused on developing and commercializing life-saving vaccines for infectious diseases. The company offers a portfolio of vaccines including IXIARO/ JESPECT against Japanese encephalitis; DUKORAL against cholera and traveler's diarrhea; and VLA1553 against chikungunya virus, with additional candidates in clinical development such as VLA15 for Lyme disease and VLA2001 for COVID-19; it provides contract development and manufacturing services for third-party vaccine projects. Valneva operates manufacturing facilities and R&D centers in Europe and Canada, targeting global markets with emphasis on travel, endemic, and emerging infectious diseases. Founded in 1994 and headquartered in Saint-Herblain, France, the company maintains subsidiaries across multiple European countries and North America. In recent developments within the last two years, Valneva completed Phase 3 trials for its Lyme disease vaccine candidate and secured strategic partnerships for commercial advancement, alongside ongoing funding efforts to support pipeline expansion.